Physician profile
Jodi Luchs
NPI 1366413023
$206,724.14
in general payments reported to CMS, 2019-2025
38 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $34K · 2021: $47K · 2022: $18K · 2023: $10K · 2024: $43K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Consulting Fee: $20K · Food and Beverage: $7,407 · Travel and Lodging: $4,168 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $41,575.00 |
| Consulting Fee | $19,950.00 |
| Food and Beverage | $7,406.65 |
| Travel and Lodging | $4,167.58 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $70,728.68 | 2019-2023 | Flarex, Tobradex St |
| Bausch & Lomb Americas INC. | $50,263.65 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Sun Pharmaceutical Industries INC. | $43,963.67 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Thea Pharma INC. | $10,469.00 | 2022-2024 | Iyuzeh |
| Abbvie INC. | $9,689.50 | 2022-2025 | |
| Allergan, INC. | $8,942.22 | 2019-2022 | |
| Alcon Vision LLC | $2,142.80 | 2019-2025 | Clareon, Argos, Rocklatan |
| Oyster Point Pharma, INC. | $1,495.14 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $1,425.48 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $1,026.45 | 2019-2024 | Omni Surgical System |
| Omeros Corporation | $1,000.00 | 2020 | |
| Shire North American Group INC | $833.17 | 2019 | |
| Tearlab Corp | $700.00 | 2023 | Tearlab Osmolarity System |
| Rxsight INC | $546.39 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $459.04 | 2021-2025 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $441.03 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $396.68 | 2023-2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Tarsus Pharmaceuticals, INC. | $390.50 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $328.43 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $216.78 | 2019 | |
| Harrow Eye, LLC | $203.06 | 2024-2025 | Vevye, Iheezo |
| Glaukos Corporation | $202.03 | 2019-2025 | Radius, Idosetr, Istent Infinite |
| Lkc Technologies, INC. | $149.44 | 2024 | |
| Aerie Pharmaceuticals, INC. | $132.59 | 2020-2021 | |
| Ocular Therapeutix, INC. | $93.13 | 2020 | |
| Ani Pharmaceuticals, INC. | $91.62 | 2024-2025 | Purified Cortrophin Gel |
| Optos, INC. | $62.42 | 2020 | |
| Carl Zeiss Meditec, INC. | $58.90 | 2025 | |
| Amgen INC. | $47.66 | 2024 | Tepezza |
| Halozyme INC | $39.07 | 2025 | Hylenex Recombinant |
| Johnson & Johnson Vision Care, INC. | $37.69 | 2023 | Tecnis Simplicity |
| Eyepoint US, INC. | $34.04 | 2019 | |
| Biotissue Holdings INC. | $32.60 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.92 | 2023 | Acthar |
| New World Medical,INC. | $31.14 | 2022 | |
| Horizon Therapeutics Plc | $18.22 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$458,742.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Luchs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.